Brain

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Hybrid, decentralized trial of bezisterim in early Parkinson’s Disease prioritizes patient access and participationCARSON CITY, Nev., June 26, 2025 (GLOBE…

6 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated…

6 months ago

Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational Highlights

Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in…

6 months ago

Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity

TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

6 months ago

Scott McGohan Launches Mental Health Engagement Catalyst One Morning with Vital Brand-Development Support from Hyperquake

DAYTON, Ohio and CINCINNATI, June 25, 2025 /PRNewswire/ -- Independent creative strategy, branding, and experience design agency Hyperquake today announced…

6 months ago

Corundum Convergence Institute and the University of Tokyo’s International Research Center for Neurointelligence Launch Inaugural Neuroscience Entrepreneurship Workshop

Neuro-inspired Computation and Entrepreneurship Workshop Will Equip the Next Generation of Neuroscience Entrepreneurs with Foundational Tools for Startup Creation TOKYO,…

6 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis…

6 months ago

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costsNEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE…

6 months ago

ORYZON to Host Virtual KOL Event on July 9, 2025

To discuss the unmet medical need in Borderline Personality Disorder (BPD) and the design of vafidemstat’s Phase III PORTICO-2 trial…

6 months ago

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104

Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive…

6 months ago